Effects of progestogens on haemostasis

Maturitas

Volumn 24, Issue 1-2, 1996, Pages 1-19

  Kuhl, Herbert ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Arteries; Cardiovascular diseases; Haemostasis; Progestogens; Veins

Indexed keywords

BLOOD CLOTTING FACTOR; CHLORMADINONE ACETATE; COLLAGEN; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ELASTIN; ESTRADIOL VALERATE; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; ETYNODIOL DIACETATE; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DOSE ORAL CONTRACEPTIVE; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NANDROLONE; NANDROLONE DERIVATIVE; NORETHISTERONE; NORGESTRIENONE; ORAL CONTRACEPTIVE AGENT; OXANDROLONE; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE; TRIACYLGLYCEROL; UNINDEXED DRUG; VASOACTIVE AGENT;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DRUG MIXTURE; ENDOTHELIUM INJURY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIPID METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; VEIN BLOOD FLOW; VEIN COMPLIANCE; VENOUS STASIS;

EID: 0029937036     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(96)00994-2     Document Type: Article

References (141)

1. Wingrave SJ. Progestogen effects and their relationship to lipoprotein changes. Acta Obstet Gynecol Scand 1982; Suppl 105: 33-36.
2. Kay CR. Progestogens and arterial disease - evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol 1982; 142: 762-765.
3. Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 158: 1646-1652.
4. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations. Br Med J 1980; I: 1157-1161.
5. Engel HJ, Engel E, Behnke K, Lichtlen P. Angiographische Befunde nach Herzinfarkt junger Frauen: Die Rolle oraler Kontrazeptiva. Herz 1987; 12: 290-295.
6. Meade TW. Effect of progestogens on the cardiovascular system. Am J Obstet Gynecol 1982; 142: 776-780.
7. Adams MR, Clarkson TB, Koritnik DR, Nash HA. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 1987; 47: 1010-1018.
8. Clarkson TB, Adams MR, Kaplan JR, Shively CA, Koritnik DR. From menarche to menopause: Coronary artery atherosclerosis and protection in cynomolgus monkeys. Am J Obstet Gynecol 1989; 160: 1280-1285.
9. Garcia Valencia V, Sanchez M, Gutierrez M, Cantabrana B, Hidalgo A. Effects of steroidal and nonsteroidal antiandrogens on the left atrium of the rat in vitro. Gen Pharmac 1991; 22: 1081-1086.
10. Huovinen K, Autio S, Kaprio J. Peroral lynestrenol and arterial disease in mentally retarded women. Acta Obstet Gynecol Scand 1988; 67: 211-214.
11. Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970; II:203-209.
12. Royal College of General Practitioners' Oral Contraceptive Study: Oral contraceptives, venous thrombosis, and varicose veins. J Roy Coll Gen Pract 1978; 28: 393-399.
13. Gerstman BB, Piper JM, Freiman JP, Tomita DK, Kennedy DL, Ferguson WJ, Bennett RC. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 1990; 19: 931-936.
14. Liskin LS, Quillin WF. Long-acting progestins - promise and prospects. Popul Rep 1983; XI: K17-K55.
15. Schwallie PC. Experience with Depo-provera as an injectable contraceptive. J Reprod Med 1974; 13: 113-117.
16. Nilsson IM, Kullander S, Astedt B. Coagulation and fibrinolytic studies during continuous use of low dose gestagen. Acta Endocrinol 1970; 65: 111-116.
17. Poller L, Thomson JM, Thomas W, Wray C. Blood clotting and platelet aggregation during oral progestogen contraception: a follow-up study. Brit Med J 1971; I: 705-707.
18. Bergsjö P, Fagerhol MK, Abildgaard U. Antithrombin III concentration in women using low-dosage progestogen for contraception. Am J Obstet Gynecol 1972; 112: 938-940.
19. Wodzicki AM, Coopland AT. Chlormadinone acetate and its effect on the hemostatic mechanism. Can Med Assoc J 1972; 107: 38-41.
20. Mink IB, Courey NG, Moore RH, Ambrus CM, Ambrus JL. Progestational agents and blood coagulation. Am J Obstet Gynecol 1972; 113: 739-743.
21. Fagerhol MK, Abildgaard U, Bergsjo P, Jacobsen JH. Oral contraceptives and low antithrombin-III concentration. Lancet 1970; i: 1175.
22. Lorrain J, Harel P. Effects of certain contraceptive hormones on blood coagulation. Fertil Steril 1972; 23: 422-427.
23. Ball MJ, Ashwell E, Gillmer MDG. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44: 223-233.
24. Conard J, Cazenave B, Samama M, Horellou MH, Zorn JR, Neau C. AT III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women. Thromb Res 1980; 675-681.
25. Korsan-Bengtsen K, Larsson B. Effect on blood coagulation and fibrinolysis in women using norethisterone or a combination of ethinyloestradiol and quingestianol. Gynecol Obstet Invest 1978; 9: 312-318.
26. Larsson-Cohn U, Fagerhol MK, Abildgaard U. Concentration of antithrombin III during combined and progestogen-only oral contraceptive treatment. Acta Obstet Gynecol Scand 1972; 51: 315-317.
27. Howie PW, Prentice CRM, Mallinson AC, Horne CHW, McNicol GP. Effect of combined oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity. Lancet 1970; ii: 1329-1332.
28. Bounameaux H, Duckert F, Walter M, Bounameaux Y. The determination of antithrombin III - Comparison of six methods. Effect of oral contraceptive therapy. Thromb Haemostasis 1978; 39: 607-615.
29. Alkjaersig N, Fletcher A, Burstein R. Association between oral contraceptive use and thromboembolism: a new approach to its investigation based on plasma fibrinogen chromatography. Am J Obstet Gynecol 1975; 122: 199-211.
30. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171-197.
31. Klehr-Bathmann I, Kuhl H. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas 1995; 21: 245-250.
32. Astedt B. Fibrinolytic activity of veins during treatment with medroxyprogesterone acetate. Acta Obstet Gynecol Scand 1972; 51: 283-286.
33. Fogh M, Knudsen JB, Gormsen J. Effect of cyproterone acetate on platelet aggregability, fibrinolytic activity and fibrinolytic capacity in normal men. Acta Endocrinol 1980; 94: 430-432.
34. Fearnly GR, Chakrabarti R. Increase of blood fibrinolytic activity by testosterone. Lancet 1962; ii: 128-132.
35. Glueck HI, Glueck CJ. Clotting mechanisms in patients with hypertriglyceridemia during therapy with anabolic or progestational drugs. Thromb Diathes Haemorrh 1973; 29: 499-509.
36. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T. The induction of a hypercoagulable state by medroxyprogesterone acetate in breast cancer patients. Jpn J Surg 1990; 20: 665-670.
37. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T. Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer. Jpn J Cancer Res 1991; 82: 420-425.
38. Nilsson TK, Tomic R, Ljungberg B. Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma. Scand J Urol Nephrol 1989; 23: 11-14.
39. Whigham KAE, Howie PW, Mack A, Prentice CRM. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol 1979; 86: 806-809.
40. Fotherby K, Saxena BN, Shrimanker K, Hingorani V, Takker D, Diczfalusy E, Landgren BM. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril 1980; 34: 131-139.
41. Fahmy K, Khairy M, Allam G, Gobran F, Alloush M. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 44 (1991) 431-444.
42. Brakman P, Sobrero AJ, Astrup T. Effect of different systemic contraceptives on blood fibrinolysis. Am J Obstet Gynecol 1970; 106: 187-192.
43. Fotherby K, Savena B, Shrimanker K, Hingorani V, Takker D, Diczfalusy E, Landgren BM. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril 1980; 34: 131-139.
44. Schwallie PC, Assenzo JR. Contraceptive efficacy study utilizing medroxyprogesterone acetate. Fertil Steril 1973; 24: 331-339.
45. Solash J, Perez R, Keates JS, et al. Hormonal steroids: effects on vascular system. Gynaecol Invest 1974; 6: 329-336.
46. Astedt B, Jeppson S, Pandoflofi M. Fibrinolytic activity of veins during use of depot-medroxyprogesterone acetate as a contraceptive. Fertil Steril 1972; 23: 489-492.
47. Oyelola OO, Thomas KD, Olusi SO. Steroidal contraceptives and changes in individual plasma phospholipids: possible role in thrombosis. Adv Contraception 1990; 6: 193-206.
48. Howard G, Myatt L, Elder MG. The effects of intramuscular norethisterone oenanthate used as a contraceptive on intravenous glucose tolerance and on blood coagulation factors VII and X. Br J Obstet Gynaecol 1977; 84: 618-621.
49. Howard G, Blair M, Fotherby K, Trayner I, Hamawi A, Elder MG. Some metabolic effects of long-term use of the injectable contraceptive norethisterone oenanthate. Lancet 1982; i: 423-425.
50. Meng YX, Virutamasen P. Effect of norethisterone enanthate on endometrial bleeding and changes in coagulation function, ovarian hormones and endometrial histology in Thai women. Contraception 1991; 44: 73-82.
51. McEwan JA, Griffin M. Long-term use of depotnorethisterone enanthate: effect on blood coagulation factors and menstrual bleeding patterns. Contraception 1991; 44: 639-648.
52. Lira P, Rivera L, Diaz S, Croxatto HB. Study of blood coagulation in women treated with megestrol acetate implants. Contraception 1975; 12: 639-644.
53. Singh K, Viegas OAC, Koh SCL, Ratnam SS. Effect of long-term use of Norplant implants on haemostatic function. Contraception 1992; 45: 203-219.
54. Singh K, Viegas OAC, Koh SCL, Ratnam SS. Effect of Norplant-2 rods on haemostatic function. Contraception 1992; 46: 71-81.
55. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemostasis 1989; 61: 65-69.
56. Aylward M. Coagulation factors in opposed and unopposed oestrogen treatment at the climacteric. Postgrad Med J 1978; 54 (Suppl 2): 31-37.
57. Notelovitz M, Kitchens C, Ware M, Hirschberg K. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 1983; 62: 596-600.
58. Gordon EM, Williams SR, Frenchek B, Mazur CA, Speroff L. Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII. J Lab Clin Med 1988; 111: 52-56.
59. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075.
60. Skartlien AH, Lyberg-Beckmann S, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. Arterioscleosis 1989; 9:798-801.
61. Winkler UH, Bühler K, Oberhoff C, Koslowski S, Hölscher T, Goitowski S, Rehage B, Schindler AE. The dynamic balance of hemostasis: a key for understanding thromboembolism in oral contraceptive users. In: Genazzani AR, Petraglia F, Boselli F, Segre A, Genazzani AD, D'Ambrogio (eds). Current research in gynecology and obstetrics. Carnforth: Parthenon, 1991; 389-394.
62. Meng YX, Jiang HY, Chen AJ, Lu FY, Yang H, Zhang MY, Shen KY, Sun DE, Shao QX, Fotherby K. Hemostatic changes in women using a monthly injectable contraceptive for one year. Contraception 1990; 42: 455-466.
63. Prasad RNV, Koh S, Ratnam SS. Effects of three types of combined O.C. pills on blood coagulation, fibrinolysis and platelet function. Contraception 1989; 39: 369-383.
64. Hunter DJS, Anderson ABM, Haddon M. Changes in coagulation factors in postmenopausal women on ethinyl oestradiol. Br J Obstet Gynaecol 1979; 86: 488-490.
65. Cohen H, Mackie IJ, Walshe K, Gillmer MDG, Machin SJ. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Br J Haematol 1988; 69: 259-263.
66. Omsjo IH, Oian P, Maltau JM, Osterud B. Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis. Acta Obstet Gynecol Scand 1989; 68: 27-30.
67. Rein H, Kjaer A, Lebech AM, Borggaard B, Schierup L, Bremmelgaard A. Metabolic changes during treatment with two different progestogens. Am J Obstet Gynecol 1990; 163: 374-377.
68. Ball MJ, Ashwell E, Jackson M, Gillmer MDG. Comparison of two triphasic contraceptives with different progestogens: Effects on metabolism and coagulation proteins. Contraception 1990; 41: 363-376.
69. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987; 157: 1042-1048.
70. Gevers Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-636.
71. Thomson JM, Poller L, Bocaz JA, Barja P, Bonnar J, Daly L et al. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 1991; 98: 1117-1128.
72. Sabra A, Bonnar J. Hemostatic system changes induced by 50 μg and 30 μg estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel. J Reprod Med 1983; 28 (Suppl): 85-91.
73. Pan JQ, Hall ER, Wu KK. Alteration of platelet responses to metabolites of arachidonic acid by oral contraceptives. Br J Haematol 1984; 58: 317-323.
74. Huch KM, Elam MB, Chesney CM. Oral contraceptive steroid induced platelet coagulant hyperactivity: dissociation of in vivo and in vitro effects. Thrombos Res 1987; 48: 41-50.
75. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993; 81: 261-264.
76. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 1977; 232: H381-H385.
77. Pilo R, Aharony D, Raz A. Testosterone potentiation of ionophore and ADP induced platelet aggregation: relationship to arachidonic acid metabolism. Thromb Haemostasis 1981; 46: 538-542.
78. Horwitz KB, Horwitz ED. Canine vascular tissues are targets for androgens, estrogens and progestins, and glucocorticoids. J Clin Invest 1982; 69: 750-758.
79. Lin AE, mcGill HC, Shain SA. Hormone receptors of the baboon cardiovascular system. Circ Res 1982; 50: 610-616.
80. Sheridan PJ, McGill HC. The nuclear uptake and retention of a synthetic progestin in the cardiovascular system of the baboon. Endocrinology 1984; 114: 2015-2019.
81. Lin AL, Shain SA, Gonzalez R. Sexual dimorphism characterizes steroid hormone modulation of rat aortic steroid hormone receptors. Endocrinology 1986; 119: 296-302.
82. Colburn P, Buonassisi V. Estrogen-binding sites in endothelial cell cultures. Science 1978; 201: 817-819.
83. Ingegno MD, Money SR, Thelmo W, Green GL, Davidian M, Jaffe BM, Pertschuk LP. Progesterone receptors in the human heart and great vessels. Lab Invest 1988; 59: 353-356.
84. Lantta M, Kärkkäinen J, Lehtovirta P. Progesterone and estradiol receptors in the cytosol of the human uterine artery. Am J Obstet Gynecol 1983; 147: 627-633.
85. Bergqvist A, Bergqvist D, Ferno M. Estrogen and progesterone receptors in vessel walls. Acta Obstet Gynecol Scand 1993; 72: 10-16.
86. Lüscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation 1993; 87 (Suppl V): V-36-V-44.
87. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982; 257: 6653-6655.
88. Ylikorkala O, Kuusi T, Tikkanen MJ, Viinikka L. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J Clin Endocrinol Metab 1987; 65: 1238-1242.
89. Witter FR, DiBlasi MC. Effect of steroid hormones on arachidonic acid metabolites of endothelial cells. Obstet Gynecol 1984; 63: 747-751.
90. Needleman SW, Parks WM. Catechol estrogens and thrombosis: differential effect of 2-hydroxyestradiol and estradiol on prostacyclin release. Contraception 1982; 26: 317-320.
91. Kjaeldgaard A, Larsson B. Fibrinolytic activity in plasma and vessels of the hind leg in rats treated with ethinylestradiol and d-norgestrel. Contraception 1984; 30: 169-178.
92. Kjaeldgaard A, Ahlesteen I, Larsson B, Astedt B. Progestogen regulation of tissue plasmingen activator in a human melanoma cell line. Thromb Res 1988; 49: 287-297.
93. Kjaeldgaard A, Larsson B, Astedt B. Regulatory effect of contraceptive steroids on the release of tissue-type plasminogen activator in vitro. Contraception 1984; 30: 355-362.
94. Hedner U, Nilsson IM, Isacson S. Effect of ethyloestrenol on fibrinolysis in the vessel wall. Br Med J 1976; II: 729-731.
95. Nilsson B, Nilsson IM, Hedner U. Delta-4-Ethylestrenol in recurrent deep venous thrombosis. Acta Med Scand 1981; 209: 45-49.
96. Taberner DA, Thomson JM, Kjoczko J. Stanazolol, fibrinolytic activators and inhibitors. Thromb Haemostasis 1983; 50: 146.
97. Fearnley GR, Chakrabarti R. Increase in blood fibrinolytic activity by testosterone. Lancet 1962; ii: 128-132.
98. Preston FE, Burakowski BK, Porter NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22: 543-551.
99. Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993; 155: 568-578.
100. Forbes TR, Glassen G. Steroid compounds and the dilatation of ovarian and uterine veins in the mouse. Am J Obstet Gynecol 1972; 113: 678-680.
101. McCausland AM, Holmes F, Trotter AD. Venous distensibility during the menstrual cycle. 1963; 86: 640-645.
102. Goodrich SM, Wood JE. Peripheral venous distensibility and velocity of venous blood flow during pregnancy or during oral contraceptive therapy. Am J Obstet Gynecol 1964; 90: 740-744.
103. Fawer R, Dettling A, Weihs D, Welti H, Schelling JL. Effect of the menstrual cycle, oral contraception and pregnancy on forearm blood flow, venous distensibility and clotting factors. Eur J Clin Pharmacol 1978; 13: 251-257.
104. Rieckert H, Schneider HJ, Schnitzer W, Hguyen-Duong H. Die Gefäßwandfunktion des kaudalen Venensystems unter detn Einfluß von Kontrazeptiva. Thromb Diathes Haemorrhag 1971; 49: 163-167.
105. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250: H1145-H1149.
106. Covelli A, Allegra C, Carlizza A, Neri A, Finsinger M. Capillary-venular changes during administration of two low-dose estrogen (EE) oral contraceptives (OC), with either desogestrel (DSG) or gestodene (GSD). XIII World Congress FlGO. Int J Gyn Obstet (Abstr Suppl) 1991; p 495.
107. Tollan A, Kvenild, Strand H, Oian P, Maltau JM. Increased capillary permeability for plasma proteins in oral contraceptive users. Contraception 1992; 45: 473-481.
108. Danforth DN, Manalo-Estrella P, Buckingham JC. The effect of pregnancy and of Enovid on the rabbit vasculature. Am J Obstet Gynecol 1964; 88: 952-962.
109. Ernst E, Schmölzl C, Matrai A, Schramm W. Hemorheological effects of oral contraceptives. Contraception 1989; 40: 571-580.
110. Derham RJ, Buchan PC. Haemorheological consequences of oestrogen and progestogen therapy. Eur J Obstet Gynecol Reprod Biol 1989; 32: 109-114.
111. Schmeller W, Federsel M, Emons G. Beinvenenhämodynamik während des weiblichen Zyklus und unter hormonaler Kontrazeption. Phlebol Proktol 1989; 18: 132-136.
112. Gelmini G, Delsignore R, Coiro V. Evaluation of erythrocyte deformability in premenopausal and postmenopausal women. Maturitas 9 (1987) 275-281.
113. Wolinsky H. Effects of estrogen and progestogen treatment on the response of the aorta of male rats to hypertension. Circ Res 1972; 30: 341-349.
114. Rönnemaa T, Järveläinen H, Lehtonen A, Grönroos M, Marniemi J, Rautio A. Growth of human aortic smooth muscle cells cultured with human serum is retarded when serum lipids are lowered by medroxyprogesterone. Atherosclerosis 1987; 67: 223-228.
115. Gammal EB. Intimal thickening in arteries of rats treated with synthetic sex hormones. Br J Exp Pathol 1976; 57: 248-254.
116. Fischer GM, Swain ML. Influence of contraceptive and other sex steroids on aortic collagen and elastin. Exp Mol Pathol 1980; 33: 15-24.
117. Fischer GM, Swain ML. Effect of sex hormones on blood pressure and vascular connective tissue in castrated and noncastrated male rats. Am J Physiol 1977; 232: H617-H621.
118. Hassager C, Jensen LT, Podenphant J, Riis BJ, Christiansen C. Collagen synthesis in postmenopausal women during therapy with anabolic steroid or female sex hormones. Metabolism 1990; 39: 1167-1169.
119. Beldekas JC, Smith B, Gersteinfeld LC, Sonnenshein GE, Franzblau C. Effects of 17β-estradiol on the biosynthesis of collagen in cultured bovine aortic smooth muscle cells. Biochemistry 1981; 20: 2162-2167.
120. Jiang C, Sarrel PM, Poole-Wilson PA, Coffins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992; 263: H271-275.
121. Sarrel PM. Sexuality and menopause. Obstet Gynecol 1990; 75: 26S-30S.
122. Sarrel P. Effects of ovarian steroids on the cardiovascular system. In: The circulation in the female (Ginsberg J, ed). Carnforth UK: Parthenon, 1989; 117-141.
123. Hillard TC, Bourne TH, Whitehead MI, Crayford TB, Coffins WP, Campbell S. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril 1992; 58: 959-963.
124. Sarrel PM. Ovarian hormones and cardiovascular function. XIII World Congress of Gynaecology and Obstetrics, 1991.
125. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Circulation 1989; 80: 198-205.
126. Jung-Hoffmann C, Kuhl H. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception 1990; 42: 423-438.
127. Green DJ, Cable NT, Rankin JM, Fox C, Taylor RR. Anabolic steroids and vascular responses. Lancet 1993; 342: 863.
128. Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-432.
129. de Ziegler D, Bessis R, Frydman R. Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone. Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone. Fertil Steril 1991; 55: 775-779.
130. de Ziegler D. Effect of progestins on vascular tone? Fertil Steril 1993; 60: 590-592.
131. Steer CV, Campbell S, Pampiglione, Kingsland CR, Mason BA, Collins WP. Transvaginal colour flow imaging of the uterine arteries during the ovarian and menstrual cycles. Hum Reprod 1990; 5: 391-395.
132. Cano A, Ballester MJ, Balanza R, Bonilla-Musoles. Effect of HRT on uterine arterial status in hypoestrogenic women. 7th International Congress on the Menopause, 1993; Abstract 116.
133. Greiss FC, Anderson SC. Effect of ovarian hormones on the uterine vascular bed. Am J Obstet Gynecol 1970; 107: 829-836.
134. Anderson SG, Hackshaw BT, Still JG, Greiss FC. Uterine blood flow and its distribution after chronic estrogen and progesterone administration. Am J Obstet Gynecol 1977; 127: 138-142.
135. Resnik R, Brink GW, Plumer MH. The effect of progesterone on estrogen-induced uterine blood flow. Am J Obstet Gynecol 1977; 128: 251-254.
136. Batra S, Bjellin L, Iosif S, Martensson L. Sjögren C. Effect of oestrogen and progesterone on the blood flow in the lower urinary tract of the rabbit. Acta Physiol Scand 1985; 123: 191-194.
137. 1-adrenergic receptors in altering uterine blood flow during the estrous cycle of gilts. Am J Obstet Gynecol 1984; 150: 480-484.
138. Byrne KB, Stanton BJ, Coupar IM, Burcher E. Effect of levonorgestrel and ethinyloestradiol on vasoconstriction in rat isolated vasculature. J Pharm Pharmacol 1988; 40: 562-566.
139. Goldstein DS, Levinson P, Keiser HR. Plasma and urinary catecholamines during the human ovulatory cycle. Am J Obstet Gynecol 1983; 146: 824-829.
140. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol 1992; 211: 163-167.
141. Garcia Valencia V, Sanchez M, Gutierrez M, Cantabrana B, Hidalgo A. Effects of steroidal and nonsteroidal antiandrogens on the left atrium of the rat in vitro. Gen Pharmacol 1991; 22: 1081-1086.